The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment

2016-01-11 12:05:36 | BioPortfolio


The aberrant expression of micro-RNAs (miRNAs) has been described in many human diseases, including schizophrenia (SZ). The previous work has indicated a strong genetic association between the miRNA-30e precursor (pre-miR-30e) and the risk of SZ. However, to date, few reports have focused on the expression level of the miR-30 family (miR-30s) and its networks of co-regulation in SZ, even in response to antipsychotic treatment. Given this, the investigator first constructed a hybrid miRNA-TF (transcription factor)-gene-PPI (protein-protein interactions) network focusing on miR-30s by bioinformatics technology. The investigator then selected several candidate miR-30s and key regulators for further validation. These candidates were then quantified by real-time quantitative PCR (qRT-PCR) in an independent cohort of 200 healthy controls and 200 drug-free SZ patients, among which were followed up by 12-week antipsychotic treatment. Furthermore, the investigator evaluated the correlation between the change in gene expression and the improvement of symptoms.


Schizophrenia is one of the most serious mental disorder,which is characterized by high prevalence rate ,high recurrence rate, could increase patients' disability and burden of disease. But the pathological mechanism is so far unknown. Until recently, more attention are focused on gene dysregulation hypothesis. The preliminary works of our laboratory prompted that microRNA-30e gene polymorphism and expression abnormal may be related to schizophrenia. Combined with previous studies showed that miRNA disorder involved in neurodevelopmental obstacle and neuropsychiatric disease, the investigators surmised: miR-30e dysregulation can impact the occurrence and development of schizophrenia. This study will carry on the multidimensional research by using the technology of neurobiology, molecular genetics,neuroimaging and so on, and integrate methods of molecular, cell, animal and human body tracking, so as to:(1) Explaining the transcription and regulation mechanisms of target genes of miR-30e,and building the gene regulatory network of schizophrenia as the core of miR-30e.(2)To investigate the pathogenesis of miR-30e participate in schizophrenia, and to evaluate the clinical value of miR-30e in peripheral blood on the disease diagnose, genotyping, predicting efficacy and ending. The object of this study is to provide new scientific data and research ideas for further exploring the neurobiological basis of schizophrenia, and recognize pathophysiological mechanisms of schizophrenia, ultimately to improve and strengthen the new situation in schizophrenia prevention.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science




Risperidone, Olanzapine, Quetiapine, Aripiprazole, Ziprasidone


First Clinical Medical College of Shanxi Medical University




Shanxi Medical University

Results (where available)

View Results


Published on BioPortfolio: 2016-01-11T12:05:36-0500

Clinical Trials [1668 Associated Clinical Trials listed on BioPortfolio]

Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole

This proposal aims to use well-validated methodologies such as dual energy x-ray absorptiometry (DEXA), frequently sampled oral glucose tolerance tests (fsOGTTs), and hyperinsulinemic eugl...

Switch Study of Existing Atypical Antipsychotics to Bifeprunox

The study will evaluate the safety and tolerability of switching subjects with schizophrenia or schizoaffective disorder from their existing antipsychotic medication to Bifeprunox.

Schizophrenia Trial of Aripiprazole

Aripiprazole will show improved effectiveness over the standard of care treatment with one of three atypical antipsychotics (olanzapine, quetiapine and risperidone).

Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients

Evaluation of the antipsychotic efficacy and safety of ziprasidone versus olanzapine, risperidone or quetiapine in patients with schizophrenia, schizoaffective and schizophreniform disorde...

Switching Medication to Treat Schizophrenia

This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatme...

PubMed Articles [764 Associated PubMed Articles listed on BioPortfolio]

An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes.

This study aimed to investigate the efficacy and tolerability of aripiprazole, olanzapine and risperidone in first-episode schizophrenia (FES).

Hospitalization risk in patients with schizophrenia treated with dose-equivalent antipsychotics.

This study compared the risk of hospitalization among adults with schizophrenia being treated with equivalent dose ranges of lurasidone versus aripiprazole, olanzapine, quetiapine, or risperidone. Adm...

Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis.

This network meta-analysis assessed the efficacy and tolerability of lurasidone versus other oral atypical antipsychotic monotherapies in adolescent schizophrenia. A systematic literature review ident...

Risk of pneumonia associated with atypical antipsychotic use in nursing home residents with Parkinson's disease.

According to the American Geriatrics Society (AGS) Beers criteria, most atypical antipsychotic (AAPs) are inappropriate in patients with Parkinson's disease (PD) due to the risk of worsening Parkinson...

The prescription patterns of second-generation antipsychotics in schizophrenia outpatient setting.

Background Schizophrenia is a chronic disorder that requires long-term treatment to achieve symptom remission and quality of life improvement. Antipsychotic medications are primary treatments for schi...

Medical and Biotech [MESH] Definitions

A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.

A benzisoxazole derivative and active metabolite of RISPERIDONE that functions as a DOPAMINE D2 RECEPTOR ANTAGONIST and SEROTONIN 5-HT2 RECEPTOR ANTAGONIST. It is an ANTIPSYCHOTIC AGENT used in the treatment of SCHIZOPHRENIA.

A dibenzothiazepine and ANTIPSYCHOTIC AGENT that targets the SEROTONIN 5-HT2 RECEPTOR; HISTAMINE H1 RECEPTOR, adrenergic alpha1 and alpha2 receptors, as well as the DOPAMINE D1 RECEPTOR and DOPAMINE D2 RECEPTOR. It is used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER and DEPRESSIVE DISORDER.

A chronic form of schizophrenia characterized primarily by the presence of persecutory or grandiose delusions, often associated with hallucination.

A type of schizophrenia characterized by abnormality of motor behavior which may involve particular forms of stupor, rigidity, excitement or inappropriate posture.

More From BioPortfolio on "The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment"

Quick Search

Relevant Topics

Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...

MicroRNAs (miRNAs)
A microRNA (abbreviated miRNA) is a small non-coding RNA molecule (containing about 22 nucleotides) found in plants, animals, and some viruses.  Key findings: miRNA is involved in the normal functioning of eukaryotic cells, so has dysregulation...

Searches Linking to this Trial